Cynomolgus IL2RA Protein

Catalog Number: **90265-CCCH**

General Information

Gene Name Synonym:

IL2RA

Protein Construction:

A DNA sequence encoding the cynomolgus IL2RA (H6WS54) (Met1-Arg213) was expressed with six amino acids (LEVLFQ) at the C-terminus.

Source: Cynomolgus

Expression Host: HEK293 Cells

QC Testing

Purity: ≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

Bio Activity:

Immobilized CD25/IL2RA Protein, Cynomolgus, Recombinant(Cat:90265-CCCH) at 2 μg/ml (100 μl/well) can bind biotinylated IL2 Protein, Human, Recombinant(ECD, hFc Tag)(Cat:11848-HNAE-B), The EC_{50} is 15-90 ng/mL.

Endotoxin:

< 1.0 EU per μg of the protein as determined by the LAL method

Predicted N terminal: Glu 22

Molecular Mass:

The recombinant cynomolgus IL2RA comprises 199 amino acids and has a calculated molecular mass of 22.4 KDa.The apparent molecular mass of the protein is approximately 38-42 KDa respectively in SDS-PAGE.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Stability & Storage:
Samples are stable for twelve months from date of receipt at -20℃ to -80℃.

Store it under sterile conditions at -20℃ to -80℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:

Protein Description

CD25 (alpha-chain of the IL-2 receptor, or IL2RA), is a type I transmembrane glycoprotein with a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. IL2RA is expressed on activated T cells and regulatory T cells and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high-affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covalently with the IL2 receptor beta and gamma chain, and subsequently initiates the intracellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling. The IL2RA (CD25) gene is a substantial component of the high-affinity receptor molecule highly expressed by activated T lymphocytes. Recently, a piece of strong evidence was obtained for the involvement of IL-2RA in conferring susceptibility to type 1 diabetes (T1D). Cancer growth and development are associated with the stimulation of the innate immune system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and its shedding into the circulation in a soluble form of SIL-2Ralpha. In most hematological malignancies, including different types of leukemias and lymphomas, SIL-2Ralpha is released directly from the surface of neoplastic cells thus reflecting the tumor bulk, turnover, and activity. Several studies have proved that not only lymphoid cancer cells but also some non-lymphoid cancer cells, express IL-2R on their surface. They include malignant melanoma and carcinomas of the kidney, head and neck, esophagus, and lung. Thus, sIL-2Ralpha is elevated in most proliferative disturbances of the hematopoietic system and many solid tumors.

References

1.Driesen J, *et al.* (2008) CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology. 213(9-10): 849-58. 2.Olejniczak K, *et al.* (2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. Med Sci Monit. 14(10): RA179-89. 3.Chistiakov DA, *et al.* (2008) The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett. 118(1): 1-5.